Humanigen inks licensing agreement with the University of Zurich to strengthen its treatment of graft-versus-host disease in leukemia patients
Humanigen Inc (OTCMKTS:HGEN) CEO Cameron Durrant tells Proactive Investors the California-based company has a new tool in its box to prevent graft-versus-host disease when treating patients with leukemia and other blood cancers.
Durrant says Humanigen has received an exclusive licensing agreement from the University of Zurich in Switzerland to utilize its GM-CSF protein neutralization technology, shown to mitigate graft-versus-host without stifling the positive effects of leukemia treatment.
Quick facts: Humanigen Inc
Market Cap: $92.48 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Humanigen Inc named herein, including the promotion by the Company of Humanigen Inc in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE